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ABSTRACT 51 
Purpose: To test the association between serum lipid levels prior to androgen deprivation therapy (ADT) 52 
and risk of CRPC and metastasis.  53 
Materials and methods: We identified 302 men in the SEARCH database who received ADT after 54 
radical prostatectomy for non-metastatic disease, never used statins before ADT, and had available serum 55 
lipid data within two years prior to ADT. Cox proportional hazards models were used to test associations 56 
between total cholesterol (<200 vs. ≥200 mg/dl), low-density lipoprotein (LDL; <130 vs. ≥130 mg/dl), 57 
high-density lipoprotein (HDL; ≥40 vs. <40 mg/dl) and triglycerides (<150 vs. ≥150 mg/dl) and risk of 58 
CRPC and metastasis after ADT, adjusting for potential confounders. In subanalyses, we restricted to men 59 
who remained statin non-users post-ADT. 60 
Results: Median follow-up was 67 months; 42 men developed CRPC and 44 metastasis. Men with 61 
elevated cholesterol had earlier ADT year and longer follow-up, and higher rates of statin use post-ADT. 62 
In multivariable analysis, total cholesterol and LDL were unrelated to CRPC. Low HDL (<40 vs. 63 
≥40mg/dL) was suggestively linked with increased risk of CRPC (HR 1.86; 95%CI 0.99-3.48), with a 64 
stronger association in men who remained statin non-users post-ADT (HR 3.64; 95%CI 1.45-9.17). 65 
Results for metastasis were similar to those found for CRPC. 66 
Conclusions: Among men with non-metastatic prostate cancer starting ADT, serum cholesterol was 67 
unrelated to CRPC or metastasis. Low HDL was suggestively associated with increased CRPC and 68 
metastasis risk, particularly in statin never-users. Further studies are needed to explore a potential role for 69 
lipids in prostate cancer progression after ADT. 70 
  71 
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INTRODUCTION  72 
 Prostate cancer is the most common non-cutaneous cancer and the second leading cause of 73 
death in US men.1 Despite widespread early responses to androgen deprivation therapy (ADT), the 74 
primary treatment for advanced and metastatic prostate cancer, a subset of tumors almost invariably 75 
progress to castration-resistant prostate cancer (CRPC). Although serum androgens are low in men with 76 
CRPC, tumor androgens in men on ADT can be sufficient to activate the AR, and a key source of 77 
intracellular androgen is de novo steroidogenesis from intratumoral cholesterol.2-4  78 
 A number of epidemiological studies found a link between higher serum cholesterol and 79 
increased risk of advanced prostate cancer and/or progression.3, 5, 6 Furthermore, mounting evidence 80 
supports an inverse association of the cholesterol-lowering statins with advanced and lethal prostate 81 
cancer risk.7 Among men starting ADT, one study found that statin users had delayed time to CRPC.8 82 
Moreover, in vitro experiments showed that statins inhibited uptake of testosterone precursor 83 
dehydroepiandrosterone sulfate by competitively binding transporter SLCO2B1.8 A large observational 84 
study reported that statin use alongside ADT was associated with reduced prostate cancer-specific and all-85 
cause mortality.9 Collectively, these data suggest the potential of targeting cholesterol homeostasis at the 86 
time of ADT to improve outcomes. 87 
 Despite strong biological rationale supporting a potential role for high cholesterol in CRPC, 88 
only one epidemiological study has examined this to date.10 The aim of our study was to examine whether 89 
lipid levels prior to ADT were associated with CRPC and metastasis risk after ADT. To test this, we used 90 
data from a retrospective cohort of prostate cancer patients in the Shared Equal Access Regional Cancer 91 
Hospital (SEARCH) database who received post-operative ADT without known metastatic disease. Our 92 
primary hypothesis was that elevated cholesterol would be associated with increased CRPC risk.  93 
 94 
MATERIALS AND METHODS 95 
Study sample 96 
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After obtaining Institutional Review Board approval, data from patients undergoing radical prostatectomy 97 
(RP; n=7,811) from 1982-2017 at eight Veterans Administration (VA) Medical Centers were combined 98 
into the SEARCH database.11 SEARCH does not include patients treated with preoperative ADT or 99 
radiation therapy. Given our goal to understand if serum lipids at ADT were associated with CRPC or 100 
metastasis risk, we excluded patients who never received ADT (n=6,466). As illustrated in 101 
Supplementary Figure 1, we excluded men who started statins before ADT, for a more accurate measure 102 
of serum cholesterol (n=653). Of 692 non-statin users who started ADT, we excluded patients with 103 
missing serum lipids (n=320), missing PSA at ADT (n=36), patients with metastases by the time of ADT 104 
(n=27), missing race (n=3), and missing pathology results (n=4), resulting in 302 men. 105 
 106 
Exposure assessment and definitions 107 
Fasting serum lipids (total cholesterol, LDL, HDL and TG) measured within two years prior to ADT were 108 
abstracted from VA computerized medical records. The VA Informatics and Computing Infrastructure 109 
(VINCI) enabled more complete abstraction of lipid data from medical records after 2000. As such, men 110 
excluded due to missing lipids had less recent year of ADT (Supplementary Table 1). In addition, these 111 
men tended to be older at ADT, were less likely to be black, had higher PSA at surgery and ADT, and 112 
were more likely to have received radiation. For men with available lipid data, recommended cut-offs for 113 
normal vs. abnormal serum levels (all in mg/dl) were selected based on National Cholesterol Education 114 
Program (NCEP)-Adult Treatment Panel (ATP) III guidelines.12 115 
 116 
Follow-up and outcome ascertainment 117 
Follow-up protocols were at the discretion of treating physicians. Pre-ADT PSA doubling time (PSADT) 118 
was calculated according to Prostate Specific Antigen Working Group guidelines.13 CRPC (primary 119 
outcome) was defined using Prostate Cancer Working Group Two criteria.14 Imaging reports (bone scan, 120 
magnetic resonance imaging, computed tomography, x‐ray) after surgery were assessed by trained 121 
personnel to determine the development of metastases (secondary outcome).  122 
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 123 
Statistical analysis 124 
 The characteristics of men excluded due to pre-ADT statin use are presented in 125 
Supplementary Table 2. Excluded men were slightly older than those included in our analysis, with higher 126 
BMI and longer time between surgery and start of ADT. In addition, excluded men had lower total 127 
cholesterol, LDL and HDL but higher triglycerides. Pathological characteristics did not differ between 128 
excluded and included men.  129 
 In line with our primary hypothesis, analysis of total cholesterol was considered primary, 130 
while analyses of LDL, HDL and TG were considered secondary. Demographic, clinical and pathologic 131 
differences between patients with normal vs. abnormal total cholesterol (<200 vs. ≥200 mg/dl) were 132 
examined using descriptive statistics.  133 
 Time from ADT initiation to CRPC was compared between normal vs. abnormal serum 134 
cholesterol groups using Kaplan-Meier plots and the log-rank test. Cox proportional hazards analysis was 135 
used to test whether serum cholesterol levels (abnormal vs. normal, and continuous in 10mg/dl 136 
increments) were associated with time to CRPC. Forward selection with entry threshold of p<0.05 was 137 
used to prevent overfitting. Candidate covariates included PSA at surgery and at ADT (continuous, log-138 
transformed), pathological grade group (1, 2-3, 4-5), positive surgical margins, extracapsular extension, 139 
seminal vesicle invasion, positive lymph nodes, age and year at ADT, race (black vs. non-black), statin 140 
use after ADT (time-dependent), radiation treatment after ADT (time-dependent), time from surgery to 141 
ADT, and PSADT (<9 months, ≥9 months, unknown). Selected covariates are listed in Table footnotes. In 142 
sensitivity analysis, given the potential role for obesity in CRPC,15 we forced BMI into our models and 143 
though this made estimates less precise, it did not appreciably change our results. In secondary analysis 144 
using the same approach as described for total cholesterol, we tested associations between LDL, HDL and 145 
TG and CRPC risk. Analyses were repeated for metastases, treated as a secondary outcome. Further 146 
secondary analyses were conducted among men who never took a statin after ADT. Race-stratified 147 
analyses showed similar findings in black and white men. 148 
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 Statistical analyses were conducted using STATA version 13.1 (Stata Corp., College Station, 149 
TX, USA). Statistical significance was two-sided with p<0.05. 150 
 151 
RESULTS 152 
Patient characteristics  153 
Of 302 men, 83 (27%) had elevated cholesterol (≥200 mg/dl) (Table 1). Men with elevated cholesterol 154 
had earlier years of surgery (2007 vs. 2011, p=0.004) and longer follow-up (82.5 vs 60.2 months; 155 
p=0.035). Men with normal cholesterol were more likely to have had radiation therapy than patients with 156 
elevated cholesterol (74% vs. 58%, p=0.005). There were no significant differences between age, race, 157 
PSA or pathological tumor features between total cholesterol groups. Men with elevated cholesterol also 158 
had higher LDL, higher HDL, and higher TG (all p≤0.009). Patients with normal total cholesterol were 159 
less likely to start statins after ADT (33% vs. 61%, p<0.001).  160 
 161 
Serum lipids and CRPC  162 
During a median follow-up of 61 months (IQR 32-108), 42 patients developed CRPC. Kaplan-Meier plots 163 
showed similar time to CRPC between men with normal vs. abnormal total serum cholesterol (Figure 1; 164 
log-rank, p=0.61), and there was no association between total cholesterol and CRPC risk on multivariable 165 
analysis (Table 2). Similarly, in secondary analyses, we found no significant associations between LDL 166 
or TG levels and CRPC risk (Table 2). However, relative to high HDL (≥40 mg/dL), low HDL (<40 167 
mg/dL) was suggestively associated with increased risk of CRPC (multivariable HR 1.86, 95%CI 0.99-168 
3.48, p=0.053).  169 
 170 
Among 178 men who never took a statin while on ADT, total cholesterol and LDL remained unassociated 171 
with CRPC risk (Table 3). However, on multivariable analysis, higher TG levels as a continuous variable 172 
were associated with increased risk of CRPC (HR 1.09, 95%CI 1.02-1.17, p=0.010). Similar to the overall 173 
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analysis, there was an increased risk of CRPC among patients with HDL <40 mg/dL who did not start a 174 
statin after ADT (multivariable HR 3.64, 95%CI 1.45-9.17, p=0.006). 175 
 176 
Serum lipids and metastases  177 
During a median follow-up of 64 months (IQR 33-112), 44 patients developed metastases. There was no 178 
association between total cholesterol, LDL or TG levels and risk of developing metastases after ADT 179 
(Table 4). Relative to patients with high HDL, those with low HDL had increased risk of metastasis 180 
(multivariable HR 2.02, 95% CI 1.11-3.70, p=0.021).  181 
 182 
Among men who did not start a statin after ADT, there was no association between total cholesterol or 183 
LDL and risk of metastasis after ADT (Table 5). When treated as a continuous variable, higher TG levels 184 
were positively associated with metastasis risk (HR 1.07, 95%CI 1.01-1.13, p=0.027), though no 185 
significant association was seen for categorical TG levels. Similar to the overall analysis, low HDL was 186 
associated with increased risk of metastasis among men who did not start statins after ADT (multivariable 187 
HR 2.64, 95%CI 1.11-6.29, p=0.028).  188 
 189 
DISCUSSION 190 
 Using data from a retrospective cohort of RP patients subsequently treated with ADT for non-191 
metastatic disease, we found no associations between serum cholesterol or LDL and risk of developing 192 
either CRPC or metastases. However, low HDL (<40mg/dl) was significantly associated with increased 193 
metastases risk and suggestively associated with increased CRPC risk, with stronger associations among 194 
men who remained statin non-users throughout follow-up. High TG was also moderately but significantly 195 
associated with increased CRPC and metastasis risk, but only in men who remained statin non-users 196 
throughout follow-up. These data suggest that low HDL and high TG may have a role in prostate cancer 197 
progression. Further investigations are required to better understand dyslipidemia at ADT as a risk factor 198 
for CRPC and/or metastases. 199 
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 We previously reported that elevated serum TG at RP was associated with increased risk of PSA 200 
recurrence, while higher total cholesterol and lower HDL were associated with increased risk of 201 
recurrence only among men with dyslipidemia.16 Others have shown no relationship between serum 202 
cholesterol and PSA recurrence after surgery,17 or even an inverse relationship.18, 19 However, potential 203 
factors influencing progression to CRPC may differ from those affecting PSA recurrence. Specifically, a 204 
key mechanism leading to CRPC development is de novo steroidogenesis from intratumoral cholesterol. 205 
Indeed, xenograft models, human prostate cancers, and prostate cancer cell lines express various 206 
functional de novo steroidogenesis-specific enzymes.20 Locke et al. showed that ex vivo CRPC explants 207 
expressed the necessary enzymes to convert the cholesterol precursor, acetic acid to dihydrotestosterone.2 208 
Mostaghel et al. found that high serum cholesterol increased prostate tumor volume and intratumoral 209 
testosterone levels in vivo.3 Moreover, in a transgenic mouse model, we found that reducing serum 210 
cholesterol lowered tumor androgens and slowed tumor proliferation.4 The potential biological 211 
significance of cholesterol in CRPC progression provided rationale to test our hypothesis.  212 
 Contrary to our hypothesis, we found no association between serum cholesterol, LDL, or TG 213 
levels and CRPC or metastasis risk among all men. Nuances between serum vs. tumor cholesterol may 214 
underlie our null findings. Specifically, strong data support the importance of altered tumor cholesterol 215 
metabolism in prostate cancer progression. For example, an epidemiological study showed that high 216 
tumor gene expression of SQLE, the second rate-limiting enzyme in cholesterol biosynthesis, was 217 
associated with increased lethal prostate cancer risk.21 Recently, our group reported that loss of the p450 218 
sterol hydroxylase, CYP27A1, was common in prostate cancer and that restoration of CYP27A1 or its 219 
metabolic end-product 27-hydroxycholesterol reduced intracellular cholesterol accumulation and 220 
decreased prostate cancer growth in vitro and in vivo.22 These data provide evidence that altered 221 
cholesterol tumor metabolism may drive lethal prostate cancer and that reducing intratumoral cholesterol 222 
could impair prostate cancer growth. However, we found no link between serum cholesterol and CRPC 223 
risk in the present analysis. It is noteworthy that serum and intratumoral cholesterol are not always 224 
correlated. In a prior study, lowering serum cholesterol via ezetimibe had no effect on xenograft growth.23 225 
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Despite lower serum cholesterol, the ezetimibe group had higher tumor cholesterol and elevated 226 
expression of LDL receptor, potentially a mechanism of resistance to serum cholesterol reduction 227 
allowing the tumor to continue to accrue sufficient cholesterol. While simply lowering serum cholesterol 228 
may be insufficient to block all prostate cancer growth, these data provide further evidence of the key role 229 
of cholesterol in prostate cancer biology. As such, our null findings regarding serum cholesterol and 230 
CRPC risk do not invalidate the hypothesis that cholesterol is crucial for CRPC, but merely suggest that 231 
serum cholesterol may not be crucial for CRPC. 232 
 Despite our null findings with respect to total cholesterol, our secondary analyses found low HDL 233 
was associated with increased metastases risk and suggestively associated with increased CRPC risk, with 234 
stronger associations among men who remained non-statin users throughout follow-up. Low HDL is part 235 
of the metabolic syndrome (MS), a group of risk factors including high blood pressure, dyslipidemia, high 236 
blood sugar and large waist circumference.24 Thus, it is possible that the association between low HDL 237 
and CRPC is mediated via other MS components, although in the present study our results were not 238 
substantially altered after stratifying models by median BMI or including BMI as an additional covariate 239 
in our models. Finally, a recent report by Sekine et al. showed that high HDL promoted proliferation and 240 
migration of androgen-independent prostate cancer cell lines in vitro,25 which at first glance appears 241 
contradictory to our findings. However, the authors demonstrated that prostate cancer cells uptake HDL 242 
more efficiently in low androgen environments via higher expression of ABCA1 receptors, which are 243 
normally downregulated by intratumoral androgens.25 More efficient HDL uptake by prostate cancer cells 244 
via this mechanism could deplete serum HDL, potentially leading to our observation that low serum HDL 245 
is linked with increased CRPC risk. Thus, further studies are required to clarify the complex biology of 246 
HDL in the context of CRPC and metastases.   247 
 Several study limitations should be considered. First, our sample size was small (n=302), 248 
particularly when restricting to statin never-users (n=178), potentially increasing the likelihood of false 249 
negative findings. We examined men who received ADT for nonmetastatic disease to create a more 250 
homogenous group, and this may limit the generalizability of our results. Moreover, as most men who 251 
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developed metastasis also developed CRPC, we cannot tease apart the potential role of cholesterol on 252 
each of these outcomes. Future studies would benefit from a larger sample size and longer follow-up in 253 
order to ascertain a greater number of events. Secondly, we assessed serum lipid levels in the 2-year 254 
period prior to ADT, but lipid levels may change over time and may be influenced by the growing tumor26 255 
and/or by prostate cancer treatment.27 As such, the optimal timing for measuring serum lipids to 256 
understand their possible association with CRPC and metastasis is unknown. Moreover, in the context of 257 
CRPC, it would be ideal to measure intratumoral cholesterol levels in addition to serum cholesterol as 258 
tumor biology may be important for understanding prostate cancer cholesterol metabolism. Again, it 259 
would be challenging to track changes over time and thus optimal timing would need to be identified. 260 
Finally, though SEARCH is racially diverse, it is largely comprised of earlier-stage patients at lower risk 261 
of progression, potentially limiting the generalizability of our findings. 262 
 In conclusion, our analyses showed that total serum cholesterol prior to ADT was not associated 263 
with CRPC risk in patients with non-metastatic prostate cancer undergoing ADT after RP. However, 264 
serum cholesterol may not always accurately reflect intratumor cholesterol, and it may be essential to 265 
measure tumor cholesterol metabolism to better understand the intricacies of cholesterol biology. Lastly, 266 
our analyses suggested that HDL and TG levels may be associated with risk of metastases and CRPC 267 
after ADT, particularly among men who remained non-statin users throughout follow-up, a point that 268 
requires further validation.  269 
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Figure legends 373 
Figure 1: Kaplan-Meier plots showing CRPC-free survival according to categories of A) total 374 
cholesterol, B) LDL, C) HDL, and D) triglyceride levels 375 
 376 
 377 
Table 1: Demographic, clinical, and pathological characteristics of patients by serum cholesterol status in 378 
the SEARCH database 379 
 Cholesterol < 200 mg/dl (n=219; 73%) 
Cholesterol ≥ 200 mg/dl 
(n=83; 27%) p-value 
Age, median (Q1-Q3) 62 (56-65) 62 (56-66) 0.88† 
Race, n (%)   0.37§ 
Black 89 (41%) 29 (35%)  
Non-black 130 (59%) 54 (65%)  
BMI (kg/m2), median (Q1-Q3) 27.1 (24.1-30.9) 27.9 (24.7-30.3) 0.36† 
Year of RP, median (Q1-Q3) 2007 (202-2012) 2006 (2002-2011) 0.24† 
Year of ADT, median (Q1-Q3) 2011 (2006-2014) 2007 (2004-2013) 0.004† 
16 
 
Follow-up, median (Q1-Q3) 60.2 (33.4-106.6) 82.5 (33.9-152.8) 0.035† 
PSA at surgery, median (Q1-Q3)* 9.1 (6.1-14.8) 9.8 (7.3-14.8) 0.15† 
PSA at ADT, median (Q1-Q3) 0.8 (0.2-3.2) 1.1 (0.3-3.4) 0.18† 
PSADT at ADT   0.84§ 
≥9 months 62 (38%) 26 (31%)  
<9 months 82 (37%) 31 (37%)  
Not calculable 75 (34%) 26 (31%)  
Months from RP to ADT, median 
(Q1-Q3) 
17.7 (4.3-64.9) 10.7 (5.2-47.1) 0.16† 
XRT, n (%) 163 (74%) 48 (58%) 0.005§ 
Statin use, n (%)   <0.001§ 
Never 150 (67%) 33 (38%)  
Started after ADT 73 (33%) 51 (61%)  
LDL, mean (SD) 98 (80-114) 140 (124-152) <0.001† 
HDL, mean (SD) 44 (35-52) 48 (39-66) 0.006† 
Triglycerides, mean (SD) 94 (68-144) 114 (76-192) 0.009† 
Pathological grade group, n (%)*   0.096§ 
1 29 (13%) 6 (7%)  
2-3 118 (54%) 39 (48%)  
4-5 70 (32%) 36 (44%)  
Positive margins, n (%)* 119 (54%) 50 (60%) 0.36§ 
Extracapsular extension, n (%)* 101 (46%) 44 (53%) 0.30§ 
Seminal vesicle invasion, n (%) 74 (34%) 27 (33%) 0.84§ 
Positive lymph nodes, n (%) 36 (16%) 14 (17%) 0.35† 
SD=standard deviation; Q1=25th percentile; Q3=75th percentile; PSA=prostate specific antigen; 380 
BMI=body mass index; RP=radical prostatectomy  381 
*reported among patients with data available  382 
p values calculated by † Wilcoxon rank-sum or § chi-square test 383 
 384 
Table 2: Hazard ratios for the association between serum lipid levels and risk of CRPC after ADT 385 
Total cholesterol <200 mg/dL ≥200 mg/dL Continuous§ 
  Events/N 27/219 15/83 42/302 
  Unadjusted Ref. 1.18 (0.62-2.24), p=0.61 0.99 (0.91-1.09), p=0.35 
  Adjusted* Ref. 0.89 (0.47-1.71), p=0.73 0.94 (0.86-1.03), p=0.21 
LDL <130 mg/dL ≥130 mg/dL Continuous§ 
  Events/N 31/232 11/70 42/302 
  Unadjusted Ref. 0.86 (0.43-1.72), p=0.67 0.98 (0.89-1.09), p=0.31 
  Adjusted* Ref. 0.67 (0.33-1.36), p=0.25 0.94 (0.85-1.04), p=0.23 
HDL ≥40 mg/dL <40 mg/dL Continuous§ 
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  Events/N 23/204 19/98 42/302 
  Unadjusted Ref. 1.81 (0.98-3.32), p=0.056 0.95 (0.80-1.14), p=0.58 
  Adjusted* Ref. 1.86 (0.99-3.48), p=0.053 0.96 (0.81-1.14), p=0.63 
Triglycerides <150 mg/dL ≥150 mg/dL Continuous§ 
  Events/N 29/219 13/83 42/302 
  Unadjusted Ref. 1.03 (0.54-1.99), p=0.92 1.00 (0.97-1.04), p=0.89 
  Adjusted* Ref. 0.85 (0.44-1.66), p=0.57 1.00 (0.97-1.03), p=0.99 
Cells display hazard ratio (95% confidence interval), p-value  386 
HDL=high density lipoprotein; LDL=low density lipoprotein 387 
§Hazard ratios are for every 10 mg/dL increase 388 
*Hazard ratios are adjusted for PSA at ADT, year of ADT, seminal vesicle invasion, and race 389 
 390 
Table 3: Hazard ratios for the association between serum lipid levels and risk of CRPC after ADT in 391 
patients who never took statins 392 
Total cholesterol <200 mg/dL ≥200 mg/dL Continuous§ 
  Events/N 16/146 6/32 22/178 
  Unadjusted Ref. 2.20 (0.86-5.65), p=0.10 1.08 (0.94-1.23), p=0.29 
  Adjusted* Ref. 1.16 (0.42-3.26), p=0.77 0.97 (0.85-1.10), p=0.62 
LDL <130 mg/dL ≥130 mg/dL Continuous§ 
  Events/N 19/150 3/28 22/178 
  Unadjusted Ref. 0.85 (0.25-2.87), p=0.30 1.05 (0.91-1.22), p=0.50 
  Adjusted* Ref. 0.51 (0.14-1.86), p=0.30 0.95 (0.81-1.11), p=0.49 
HDL ≥40 mg/dL <40 mg/dL Continuous§ 
  Events/N 11/127 11/51 22/178 
  Unadjusted Ref. 2.86 (1.24-6.60), p=0.014 0.91 (0.70-1.17), p=0.45 
  Adjusted* Ref. 3.64 (1.45-9.17), p=0.006 0.94 (0.71-1.25), p=0.68 
Triglycerides <150 mg/dL ≥150 mg/dL Continuous§ 
  Events/N 16/142 6/36 22/178 
  Unadjusted Ref. 1.64 (0.63-4.24), p=0.31 1.05 (0.99-1.11), p=0.11 
  Adjusted* Ref. 1.57 (0.56-4.42), p=0.39 1.09 (1.02-1.17), p=0.010 
Cells display hazard ratio (95% confidence interval), p-value  393 
HDL=high density lipoprotein; LDL=low density lipoprotein 394 
§Hazard ratios are for every 10 mg/dL increase 395 
*Hazard ratios are adjusted for PSA at ADT, year of ADT, seminal vesicle invasion, and race 396 
 397 
Table 4: Hazard ratios for the association between serum lipid levels and risk of metastases after ADT 398 
Total cholesterol <200 mg/dL ≥200 mg/dL Continuous§ 
  Events/N 30/219 14/83 44/302 
  Unadjusted Ref. 1.01 (0.53-1.91), p=0.98 0.98 (0.90-1.07), p=0.69 
  Adjusted* Ref. 0.85 (0.44-1.63), p=0.62 0.95 (0.87-1.04), p=0.30 
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LDL <130 mg/dL ≥130 mg/dL Continuous§ 
  Events/N 33/232 11/70 44/302 
  Unadjusted Ref. 0.85 (0.43-1.70), p=0.65 0.97 (0.88-1.07), p=0.99 
  Adjusted* Ref. 0.77 (0.38-1.54), p=0.45 0.95 (0.86-1.05), p=0.34 
HDL ≥40 mg/dL <40 mg/dL Continuous§ 
  Events/N 22/204 22/98 44/302 
  Unadjusted Ref. 2.17 (1.20-3.92), p=0.010 0.95 (0.79-1.13), p=0.55 
  Adjusted* Ref. 2.02 (1.11-3.70), p=0.021 0.96 (0.80-1.15), p=0.65 
Triglycerides <150 mg/dL ≥150 mg/dL Continuous§ 
  Events/N 32/219 12/83 44/302 
  Unadjusted Ref. 0.86 (0.44-1.67), p=0.66 1.00 (0.96-1.03), p=0.68 
  Adjusted* Ref. 0.71 (0.36-1.40), p=0.33 0.99 (0.95-1.02), p=0.48 
Cells display hazard ratio (95% confidence interval), p-value  399 
HDL=high density lipoprotein; LDL=low density lipoprotein 400 
§Hazard ratios are for every 10 mg/dL increase 401 
*Hazard ratios are adjusted for PSA at ADT, year of ADT, seminal vesicle invasion, and race 402 
 403 
Table 5: Hazard ratios for the association between serum lipid levels and risk of metastasis after ADT in 404 
patients who never took statins 405 
Total cholesterol <200 mg/dL ≥200 mg/dL Continuous§ 
  Events/N 19/146 6/32 25/178 
  Unadjusted Ref. 1.84 (0.73-4.63), p=0.19 1.06 (0.94-1.20), p=0.36 
  Adjusted* Ref. 1.19 (0.45-3.16), p=0.73 1.00 (0.88-1.13), p=0.96 
LDL <130 mg/dL ≥130 mg/dL Continuous§ 
  Events/N 23/150 2/28 25/178 
  Unadjusted Ref. 0.46 (0.11-1.96), p=0.29 1.00 (0.87-1.16), p=0.96 
  Adjusted* Ref. 0.36 (0.08-1.60), p=0.18 0.94 (0.80-1.09), p=0.38 
HDL ≥40 mg/dL <40 mg/dL Continuous§ 
  Events/N 14/127 11/51 25/178 
  Unadjusted Ref. 2.13 (0.97-4.72), p=0.060 0.99 (0.80-1.23), p=0.95 
  Adjusted* Ref. 2.64 (1.11-6.29), p=0.028 1.01 (0.79-1.30), p=0.91 
Triglycerides <150 mg/dL ≥150 mg/dL Continuous§ 
  Events/N 20/142 5/36 25/178 
  Unadjusted Ref. 1.00 (0.37-2.66), p=0.99 1.03 (0.98-1.09), p=0.27 
  Adjusted* Ref. 1.21 (0.42-3.46), p=0.72 1.07 (1.01-1.13), p=0.027 
Cells display hazard ratio (95% confidence interval), p-value  406 
HDL=high density lipoprotein; LDL=low density lipoprotein 407 
§Hazard ratios are for every 10 mg/dL increase 408 
*Hazard ratios are adjusted for PSA at ADT, year of ADT, seminal vesicle invasion, and race 409 
 410 
